fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Successful penicillin allergy de-labelling

Written by | 24 Mar 2025

29th EAHP Congress highlights Approximately 10% of inpatients are labelled as ‘allergic to penicillin’ but the vast majority have not experienced a true allergic reaction. Having a penicillin… read more.

Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies – Roche

Written by | 15 Mar 2025

Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further evidence supporting the… read more.

FDA has approved Odactra tablet for use in young children with house dust mite allergy – ALK

Written by | 12 Mar 2025

ALK announced that the FDA has approved ALK’s Odactra tablet for use in young children with house dust mite (HDM) allergy.Odactra is now indicated to treat HDM-induced allergic… read more.

Penicillin allergy delabeling in syphilis patients assists in furthering treatment

Written by | 28 Oct 2024

About 10% of Americans believe they are allergic to penicillin, and approximately 90% of those patients are not actually allergic. As a result, those with the penicillin allergy… read more.

European Commission approves EUR Neffy (epinephrine nasal spray) for emergency treatment of severe allergic reactions in adults and children – ARS Pharma

Written by | 7 Sep 2024

ARS Pharmaceuticals, Inc. announced the European Commission’s approval of EURneffy for emergency treatment of severe allergic reactions in adults and children weighing at least 30 kilograms. This approval… read more.

UCB to accelerate innovation and strategic partnerships, divesting mature product portfolio in China to CBC Group.

Written by | 2 Sep 2024

UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.

Fasenra (benralizumab) approved in China for the treatment of severe eosinophilic asthma – AstraZeneca

Written by | 24 Aug 2024

AstraZeneca’s Fasenra (benralizumab) has been approved in China by the country’s National Medical Products Association (NMPA) for the maintenance treatment of patients 12 years of age and older… read more.

FDA approval of neffy (epinephrine nasal spray), the first and only needle-free treatment for type I allergic reactions, including anaphylaxis – ARS Pharmaceuticals

Written by | 10 Aug 2024

ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced… read more.

High levels of ozone and grass pollen expected for Paris Olympics/Paralympics

Written by | 27 Jul 2024

High levels of the respiratory irritant ozone and grass pollen are likely during the 2024 Olympic and Paralympic Games if hot, sunny weather prevails, suggests an analysis of… read more.

Removal of incorrect penicillin allergy labels by non-specialist healthcare professional feasible

Written by | 23 Mar 2024

Patients who may have been mis-labelled as allergic to penicillin could be safely offered a dose of the oral antibiotic to demonstrate that they could take it without… read more.

New England Journal of Medicine publishes phase III data showing Xolair (omalizumab) significantly reduced allergic reactions across multiple foods in people With food allergies – Genentech/Roche

Written by | 29 Feb 2024

Genentech, a member of the Roche Group, announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and… read more.

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies – Genentech/Roche + Novartis

Written by | 20 Feb 2024

Roche announced that the FDA has approved Xolair (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.